Section Arrow
EXEL.NASDAQ
- Exelixis
Quotes are at least 15-min delayed:2025/11/17 07:48 EST
Pre Market
Last
 41.85
+0.2 (+0.48%)
Bid
40.8
Ask
43.7
High 41.85 
Low 41.85 
Volume 33 
Regular Hours
Last
 41.65
-0.7 (-1.65%)
Day High 
42.59 
Prev. Close
42.35 
1-M High
43.72 
Volume 
2.57M 
Bid
40.8
Ask
43.7
Day Low
41.23 
Open
41.93 
1-M Low
33.755 
Market Cap 
11.35B 
Currency USD 
P/E 17.79 
%Yield -- 
10-SMA 40.69 
20-SMA 39.41 
50-SMA 39.4 
52-W High 49.62 
52-W Low 31.9 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
2.38/3.13
Enterprise Value
11.55B
Balance Sheet
Book Value Per Share
8.06
Cash Flow
Cash Flow Yield
0.07
Income Statement
Total Revenue
10.50M
Operating Revenue Per Share
6.62
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
Pre Market 0.103 -0.0033 -3.10%
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
Pre Market 3.51 +0.76 +27.64%
IVVDInvivyd2.35+0.58+32.77%-- 
Pre Market 2.32 -0.03 -1.28%
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
Pre Market 0.265 +0.0467 +21.39%
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Pre Market 4.18 +0.04 +0.97%
Quotes are at least 15-min delayed:2025/11/17 07:48 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.